Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Shulman

Showing results (241-250 of 282) with videos related to

Pageof 29
Sort By:
JCO Global Oncology|July 24, 2020
State of Cancer Control in Rwanda: Past, Present, and Future OpportunitiesFidel Rubagumya, Ainhoa Costas-Chavarri, Achille Manirakiza, et al.
Journal of the American Medical Informatics Association : JAMIA|January 22, 2015
Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarizationJeremy L Warner, Suzanne E Maddux, Kevin S Hughes, et al.
The Lancet. Oncology|August 8, 2015
Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experienceSara Stulac, Agnes Binagwaho, Neo M Tapela, et al.
Journal of Oncology Practice|September 19, 2014
Bending the cost curve: a unique collaboration between radiation oncologists and Blue Cross Blue Shield of Massachusetts to optimize the use of advanced technologyLee Steingisser, Brian Acker, Stuart Berman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancerJoseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)Lawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 1, 2015
Young women with breast cancer in the United States and South Korea: comparison of demographics, pathology and managementByung Ho Son, Laura S Dominici, Fatih Aydogan, et al.
The Lancet. Oncology|March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology CommissionHedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
The Oncologist|November 10, 2018
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101Myra Barginear, Amylou C Dueck, Jacob B Allred, et al.
Pageof 29

Showing results (241-250 of 282) with videos related to

Sort By:
Pageof 29
JCO Global Oncology|July 24, 2020
State of Cancer Control in Rwanda: Past, Present, and Future OpportunitiesFidel Rubagumya, Ainhoa Costas-Chavarri, Achille Manirakiza, et al.
Journal of the American Medical Informatics Association : JAMIA|January 22, 2015
Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarizationJeremy L Warner, Suzanne E Maddux, Kevin S Hughes, et al.
The Lancet. Oncology|August 8, 2015
Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experienceSara Stulac, Agnes Binagwaho, Neo M Tapela, et al.
Journal of Oncology Practice|September 19, 2014
Bending the cost curve: a unique collaboration between radiation oncologists and Blue Cross Blue Shield of Massachusetts to optimize the use of advanced technologyLee Steingisser, Brian Acker, Stuart Berman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancerJoseph A Sparano, Lori J Goldstein, Barrett H Childs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)Lawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 1, 2015
Young women with breast cancer in the United States and South Korea: comparison of demographics, pathology and managementByung Ho Son, Laura S Dominici, Fatih Aydogan, et al.
The Lancet. Oncology|March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology CommissionHedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
The Oncologist|November 10, 2018
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101Myra Barginear, Amylou C Dueck, Jacob B Allred, et al.
Pageof 29